Clinical trial
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
NCT00431275 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00431275 |
|---|---|
| Title | Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody |
| Official title | An Open Label, Randomized Clinical Comparability Study Of The Current Liquid And Commercial Liquid Formulations |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | CP-675, 206 |
| Enrollment | 85 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Feb 5, 2007 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: